Table 3. Outcomes of IHSP With Different Clinical Variables.
| Clinical variable | Improved | Partially improved | Not improved | Total |
|---|---|---|---|---|
| Course of disease | ||||
| Acute (≤ 24 h) | 1 (25%) | 1 (25%) | 2 (50%) | 4 |
| Progressive (> 24 h) | 10 (59%) | 5 (29%) | 2 (12%) | 17 |
| Clinical features | ||||
| UMN signs | 5 (50%) | 1 (10%) | 4 (40%) | 10 |
| CSF findings | ||||
| Elevated proteins and leukocyte | 4 (80%) | 0 | 1 (20%) | 5 |
| Inflammatory markers | ||||
| Elevated ESR, CRP and RA | 3 (37.5%) | 3 (37.5%) | 2 (25%) | 8 |
| No. of spinal segments | ||||
| ≥ 6 | 5 (45.4%) | 4 (36.3%) | 2 (18.1%) | 11 |
| ≤ 5 | 6 (60%) | 2 (20%) | 2 (20%) | 10 |
| Type of managementa | ||||
| Surgical | 3 (75%) | 1 (25%) | 0 | 4 |
| Conservative | 4 (100%) | 0 | 0 | 4 |
| Both surgical and conservative | 4 (30.7%) | 5 (38.5%) | 4 (30.7%) | 13 |
| Location of IHSP | ||||
| Anterior and posterior | 1 (33.3%) | 2 (66.6%) | 0 | 3 |
| Anterior | 3 (75%) | 0 | 1 (25%) | 4 |
| Posterior | 2 (33.3%) | 2 (33.3%) | 2 (33.3%) | 6 |
| Circumferential | 4 (57.1%) | 2 (28.5%) | 1 (14.2%) | 7 |
aInitial intervention was considered in type of management. CRP: C-reactive protein; CSF: cerebrospinal fluid; ESR: erythrocytic sedimentation rate; IHSP: idiopathic hypertrophic spinal pachymeningitis; RA: rheumatoid arthritis; UMN: upper motor neuron.